Context Therapeutics Inc. Notified of Nasdaq Minimum Bid Price Deficiency

What Happened

• Context Therapeutics Inc. (CNTX) announced on an 8-K that Nasdaq sent a written Notification Letter on July 29, 2026, stating the company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The letter does not immediately affect the listing or trading of CNTX shares.

Key Details

• Nasdaq provided an initial 180-calendar-day cure period ending January 25, 2027, to regain compliance.
• To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days (unless Nasdaq extends this requirement).
• If not regained, CNTX may qualify for a second 180-day compliance period only if it meets other Nasdaq listing standards and notifies Nasdaq of its intent to cure; Nasdaq will review eligibility.
• The company may appeal any delisting determination to a Nasdaq Hearings Panel; the 8-K was signed by CEO Martin A. Lehr on July 31, 2026.

Why It Matters

• For investors, this is a notice of heightened listing risk: failure to meet the $1.00 minimum could lead to delisting proceedings, which can reduce liquidity and shareholder value. The company is monitoring the bid price and evaluating options to regain compliance, but there is no guarantee it will succeed or obtain additional relief from Nasdaq.